Status:
COMPLETED
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
Lead Sponsor:
Sandoz
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guid...
Eligibility Criteria
Inclusion
- must be able to speak, read, and understand English
- exhaled Nitrous Oxide levels must be greater than or equal to 60 ppb at screening and greater than or equal to 55 ppb at Visits 2, 9, and 16
- must have history of at least 6 months of chronic, but stable asthma
- except for the presence of asthma, subjects must be in general good health
Exclusion
- past or present history of experiencing allergic reaction to medications used in this study
- subjects must not be receiving ongoing regular treatment with inhaled corticosteroids
- subjects must not have ragweed allergy
- subjects must have no recent history of respiratory infections for at least 1 month prior to screening and until the end of the study
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00927758
Start Date
June 1 2009
End Date
December 1 2009
Last Update
March 29 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610-0486
2
CompleWare
Iowa City, Iowa, United States, 52244
3
University of Wisconsin
Madison, Wisconsin, United States, 53792